2014 Annual Report

2014
annual
report
Research, patient care
and innovation
to the benefit of the patient
Together, let’s beat cancer.
www.institut-curie.org
CONTENTS
P03
EDITORIAL
P04
ABOUT THE INSTITUTE
P06
HIGHLIGHTS
P08
RESEARCH
P10
PATIENT CARE
P12
ADVANCED TRAINING
P14
CONSERVING SCIENTIFIC
HERITAGE
P16
ACKNOWLEDGEMENTS
P17
FUNDING MODEL
CREDITS
P18
INSTITUT CURIE PRESIDENT’S OFFICE
FINANCIAL INFORMATION
AUGUST 2015 – PHOTO CREDITS: ÉRIC BOUVET,
AND FINANCIAL MANAGEMENT DEPARTMENT –
OLIVIER COCHET-ESCARTIN, CHRISTOPHE HARGOUES,
ALEXANDRE LESCURE, PEDRO LOMBARDI, NOAK/LE BAR
FLORÉAL, BENOÎT RAJAU, THIBAUT VOISIN/INSTITUT CURIE
– DESIGN AND PRODUCTION: ALL CONTENTS – CONTENT:
ALL CONTENTS – PRINTING: ALL CONTENTS – PRINTED WITH
VEGETAL INK ON PAPER FROM SUSTAINABLY MANAGED
FORESTS COMPLIANT WITH ENVIRONMENTAL STANDARDS.
2 - ANNUAL REPORT 2014 - INSTITUT CURIE
• EDITORIAL •
EDITORIAL
2014
A PREPARATORY
YEAR FOR
THE 2015-2020
PROJECT
I
n 2014, the first year of my term, we focused on three major projects:
balancing the Hospital Group budget, implementing recommendations
from the French Court of Auditors, and, above all, planning for our future
and our new project.
Following a projected deficit of €10 million in 2014, we are now on track to balance
the Hospital Group budget in 2015 thanks to the efforts of all employees and the
yearlong push for structural reform.
The Court of Auditors confirmed that we had used public donations appropriately,
while also suggesting improvements to governance and organization. I have followed
two guiding principles since my arrival: transparency with the Board of Directors
and ringfencing funding.
We also worked with all stakeholders to develop our 2015-2020 project, which
refocuses our efforts on the key field of cancer biology. In the pioneering, humanist
spirit of Marie Curie, another main theme of the project is openness towards partners
and patients alike.
Together we have laid the groundwork for the MC21 Project, which will enable us to
become a major cancer center combining excellence in research and innovative
treatments available to all. Our aim is to uphold the legacy of the Curie family while
reinventing the treatment-research model that they pioneered.
The institute has always been adept at delivering scientific discoveries to patients,
an achievement made possible by its employees, partners and by the generosity
of its donors and corporate patrons, to whom we express our gratitude.
PROF. THIERRY PHILIP
PRESIDENT
3
ABOUT THE INSTITUTE
RESEARCH,
TREAT, TRAIN
AND CONSERVE
Created on the basis of the « basic research to innovative care » model originally
devised by Marie Curie, Institut Curie operates one of the largest cancer research centers
in Europe and a leading-edge hospital group that treats all types of cancer, including
breast, eye and childhood cancer, as well as the rarest forms of the disease.
INTERNATIONALLY RENOWNED
RESEARCH AND TREATMENT
Institut Curie effectively combines international
multidisciplinary research with excellence in
cancer medicine. The Research Center spearheads
innovation in all aspects of cancer research,
from the fundamental mechanisms related
to the growth of the disease, to emerging diagnosis
techniques and therapeutic approaches.
Treatment is provided at the Hospital Group,
a pioneer in precision medicine that cares for
patients diagnosed with all types of cancer.
THE PAST, PRESENT AND FUTURE OF SCIENCE
Training provides a means for Institut Curie
to attract top talent and cultivate the level
of expertise required to secure the future
of innovation in the foundation’s research
laboratories and hospital. The institute also
helps pass on the history of science and the
Curie family in particular, through the Curie
Museum and its collections.
THE INSTITUTE’S FOUR MISSIONS
01 RESEARCH
Fighting cancer through a combination
of transdisciplinarity, medical and
scientific potential, and innovation.
03 ADVANCED TRAINING
Spreading knowledge that advances
science and treatment.
4 - ANNUAL REPORT 2014 - INSTITUT CURIE
02 PATIENT CARE
Making patients the top priority to
ensure they receive comprehensive
care and tailored treatment.
04 CONSERVATION OF SCIENTIFIC HERITAGE
The Curie Museum is a repository
for the history of the Curie family
and the foundation’s illustrious
historical roots.
• ABOUT THE INSTITUTE •
KEY FIGURES
14,300 active patients
77 nationalities represented
among the Institut Curie staff
1ST in breast
cancer surgery
(Ranking compiled by Notre Temps magazine in
partnership with L’Express)
507 medical and scientific
3,300 Employees
articles published in leading
international journals
(2014 inCities figures)
(Hospital: 2,200 – Research: 1,100)
doctors, researchers, caregivers, students,
administrative and
technical staff
83
More than
1,000 students
and postdoctoral researchers worked
at the institute in 2014
research teams
34
private-sector partners
204 CLINICAL STUDIES
900 volunteers
5
HIGHLIGHTS
2014
HIGHLIGHTS
Radiation biology & Chemistry, cell signaling and cancer
Radiotherapy “flashes” to reduce side effects
Treating hard and fast seems to be a good way to limit the side effects of
radiotherapy. This is the discovery made by researchers at Institut Curie, Inserm
and the Vaud University Hospital, published in Science Translational Medicine.
Most equipment currently in use is not powerful or accurate enough for this
technique, but the device being installed at the Institut Curie Proton therapy
center will open the door to a pre-clinical trial.
HOPE BLOSSOMS
A Daffodil for Curie
Hope blossomed throughout France during the 10th annual
A Daffodil for Curie charity event. 320 walkers and runners,
200 volunteers, companies, institutional partners, media
outlets and a large number of donors all helped support
the event, which collected €220,000.
RADIOTHERAPY
CUTTING-EDGE TECHNICAL FACILITIES
In Saint-Cloud, the institute added two new
machines at its radiotherapy facilities: Truebeam™
and Novalis™. The facilities were already among the
most comprehensive in Europe, offering
tomotherapy in Paris and proton therapy in Orsay.
The precision of the new equipment will enable the
institute to perform hypofractionated and
stereotactic treatments (or “radiosurgical”
procedures), as well as to expand its treatment
indications.
6 - ANNUAL REPORT 2014 - INSTITUT CURIE
• HIGHLIGHTS •
COLLABORATIVE RESEARCH
CELL MIGRATION: THE ART
OF CHOOSING A GOOD LEADER
Collaborative research by physicists
and biologists at Institut Curie has
found that migrating cells, which
maintain strong interactions,
designate one cell in the group
to be the leader, which all the others
follow. In an article published in
Nature Cell Biology, the researchers
explained that this kind of collective
cell migration often occurs during
the initial development of numerous
tumors.
INTERNATIONAL
The institute exports its
expertise to China
Institut Curie took part in a
three-day training program in Wuhan
conducted by Immunocan, a joint
Chinese and European consortium,
and the Sino-French School of
Oncology. During the program,
80 young professionals learned
the fundamentals of oncology.
HONOR
Geneviève Almouzni
wins Grand Prix award
Fondation pour la Recherche Médicale (FRM)
awarded its Grand Prix honor to Research
Center director Geneviève Almouzni, PhD,
for her exceptional contribution to medical
knowledge and understanding of genomic
organization.
7
RESEARCH
01 INNOVATIVE,
INTERDISCIPLINARY
RESEARCH
“Promoting cutting-edge research
at the Institut Curie Research
Center – an internationally
recognized organization in the fight
against cancer – requires
a combination of effective,
interdisciplinary collaboration,
the influx of new ideas that comes
from supporting young researchers,
and the knowledge sharing that
results from the reach of our work
both in France and abroad.”
Geneviève Almouzni, PhD
DIRECTOR OF THE RESEARCH CENTER
R
esearchers at Institut Curie are making
promising new discoveries through
a cross-disciplinary approach that
is improving knowledge of mechanisms
that could lead to new forms of
treatment. The foundation’s expert research
teams published their findings throughout the year
in leading international journals.
BLOCKING THE GROWTH OF MEDULLOBASTOMA
Medulloblastoma is the most common malignant
brain tumor found in children and develops in the
cerebellum. An “Investments for the Future”
research team (CNRS/Inserm/Institut Curie) formed
8 - ANNUAL REPORT 2014 - INSTITUT CURIE
in 2010 has discovered how the Atoh1 protein
is regulated. This breakthrough, published in
Developmental Cell, paves the way for new
therapeutic approaches. The lead is all the more
promising given that a number of drugs are already
being tested.
THE FIRST GLOBAL OVERVIEW OF YEAST GENE
DELETION MUTANTS
Geneticists recently identified possible causes for
mutations in cancer cells by studying a normal wild
strain and nine mutant strains of the yeast species
Saccharomyces cerevisiae. These findings were
published in PNAS and provide clues for identifying
the human genes involved in cancer predisposition.
The team is looking to collaborate with international
partners to advance this research and devise early
detection and treatment techniques.
COLON CANCER: TWO GENETIC ALTERATIONS
THAT CAUSE METASTASIS
One of the major challenges in colon cancer
treatment is successfully treating the disease
when metastases are present. A group of biologists,
bioinformaticians and doctors joined forces to
describe—both theoretically and experimentally—
the combination of two genetic alterations
responsible for tumor growth, in the journal Nature
Communications. In addition to providing insight
into tumor progression, the model of colon cancer
developed by the team can be used to test new
therapies that block metastasis.
In 2014, the institute sought to give fresh impetus
to multi-scale physics, chemistry and biology
research by creating the Chemical Biology of
Membranes and Therapeutic Delivery laboratory
(CNRS/Inserm/Institut Curie) led by Inserm Research
Director Ludger Johannes, PhD. The laboratory
works to discover new therapeutic approaches.
83
teams WORKING IN
PARTNERSHIP WITH CNRS,
Inserm and universities
VIEWPOINT
A series of validation
milestones mark the
transition from basic
research to the
pharmaceutical industry.
“What is extraordinary
about Institut Curie is
that we have the full
range of competencies
required to take the
process from start to
finish. I’m responsible
for developing
applications based on
discoveries as quickly as
possible, working with
both internal and
external stakeholders.”
NATHALIE AMZALLAG,
PHD, Research Engineer
and Project Manager,
Cancer Immunotherapy
9
• RESEARCH •
HOW THE SHIGA TOXIN CROSSES THE CELLULAR
THRESHOLD
How do cells ingest pathogenic agents bound to
their surfaces in order to trigger an intracellular
response? Biologists used the Shiga toxin, a
pathogenic agent produced by intestinal bacteria,
and a minimal model membrane system designed
in collaboration with biophysicists, to advance
their understanding of this cell entry mechanism.
They detailed this new stage in an unconventional
endocytosis mechanism in Nature. The fundamental
knowledge they uncovered could help find
mechanisms for transporting medicine in certain
cells, inducing an anti-tumoral or anti-viral immune
response, or even giving false “orders” to tumor cells.
PATIENT CARE
02 PERSONALIZING
PATIENT CARE
“Our priority is to ensure
patients are the central focus
of all our activities, to ensure
they receive care with a resolutely
human touch. We also offer
increasingly innovative techniques
in surgery and chemotherapy as
well as radiotherapy,
an area of excellence for
the institute since its inception.”
DR. MARC ESTÈVE,
DIRECTOR OF THE HOSPITAL GROUP
T
he institute continually reassesses its
methods and innovates in order to
provide patients with the best possible
care. One major change in 2014 was the
rise in prominence of outpatient surgery,
which was met with approval by patients. The
researchers also made significant advances in
understanding tumors, in particular through a
large-scale trial with over 700 participants and
research on circulating tumor cells.
OUTPATIENT SURGERY TAKES ON CENTRAL ROLE
While the institute has performed ambulatory surgery
since the 1970s, the creation of a dedicated
outpatient unit in 2012—primarily for breast cancer
10 - ANNUAL REPORT 2014 - INSTITUT CURIE
treatment—ushered in a new era for both patients and
caregivers. The proportion of outpatient procedures
for breast cancer at the institute shot up from 15 to
50% over the course of 2 years. Over 90% of patients
expressed satisfaction with their treatment and
operating room procedures in a questionnaire
conducted one year after the outpatient unit opened.
The results of the survey were presented at the
institute’s first conference on the theme “Breast
cancer and outpatient surgery – Patients, caregivers
and new methods of organizing treatment,” held on
September 26, 2014. The event provided a forum for
topics related to therapeutic care: the current
situation in France and the outlook for future
development, as well as hospitality and safety of care.
SHIVA TRIAL: FROM CONCEPT TO REALITY
The SHIVA trial stands among the institute’s seminal
clinical research projects, with more than 700
patients taking part. An innovative example of
precision medicine, the trial proved that it was
possible to develop a genetic map of a patient’s
tumor in less than four weeks, in order to provide
pinpoint treatment. The project also demonstrated
the effectiveness of taking an interdisciplinary
approach and fostering a close working relationship
between doctors, patients, biological-platform
researchers and engineers, non-medical caregivers
and clinical research staff.
PROTON THERAPY: EXTENDING INDICATIONS
Proton therapy is an ultra-precise form of
radiotherapy that treats tumors while limiting
irradiation in adjacent tissue. Formerly reserved for
intracranial tumors, this radiotherapy technique is
now available to patients with extracranial tumors.
MORE THAN 2,200 PATIENTS
TOOK PART IN CLINICAL STUDIES
VIEWPOINT
“Following the
documentary Healing
Our Perceptions:
Rebuilding Life After
A Mastectomy, Institut
Curie’s Info-Sein group
produced a web
documentary available
online for women
coping with a surgical
ablation in the breast
after cancer. Its aim is
to guide patients and
their loved ones as they
find their own path to
surgical or other forms
of reconstruction—a
step that isn’t always
covered by
oncologists.”
DR. SÉVERINE ALRAN,
Surgical Oncologist,
Head of the Outpatient
Surgery Unit
11
• PATIENT CARE •
CIRCULATING TUMOR CELLS: A NEW SURVIVAL
INDICATOR
Research on circulating tumor cells is expected to
make a major impact on early diagnosis of relapses,
personalized treatment and assessment of
treatment effectiveness. At Institut Curie, doctors
are demonstrating how these cells provide
additional information for the prognosis of patients
who have metastatic cancer. In March 2014, the
prestigious journal The Lancet Oncology published
the foundation’s overview of all the studies on this
type of cancer conducted in Europe.
ADVANCED TRAINING
03 ADVANCED TRAINING:
INVESTING
IN THE FUTURE
“The main aims of the institute’s Training
Unit are to use the international reach of our
programs to promote the exchange of ideas
and the emergence of new lines of research,
to work with students to promote their
research work, and to further develop
courses that build stronger ties between
research and the hospital.”
Graça Raposo, PhD
DEPUTY DIRECTOR OF ADVANCED TRAINING
AT THE RESEARCH CENTER
“The missions of the Training Unit at
Institut Curie are to teach fundamental and
translational research to as many young
doctors as possible, to help develop medical
and scientific careers by offering positions in
renowned laboratories, and to leverage our
expertise through the development of
specific training.”
PRof. Roman Rouzier,
DEPUTY DIRECTOR OF TRAINING
AT THE HOSPITAL GROUP
PROFESSOR OF SURGERY AT THE UNIVERSITY
OF VERSAILLES SAINT-QUENTIN
12 - ANNUAL REPORT 2014 - INSTITUT CURIE
T
SARAH WATSON, DOCTOR AND RESEARCHER
Since 2010, Institut Curie has awarded scholarships
to interns, assistants and pharmacists seeking to
carry out science theses at the Research Center or
Department of Translational Research. Following a
selection process, Sarah Watson began her science
thesis at the Institut Curie/Inserm/Paris Descartes
University Genetics and Cancer Biology Unit. Her
work pertains to the study of genetic anomalies
associated with the Ewing family of sarcomas—
bone cancer found in children and adolescents—
Founding member of
242
PhD students in science
and aims to provide doctors with more prognostic
tools to guide their therapeutic choices. The
scholarship represents an excellent opportunity
and compares very favorably with others of the
same type. A graduate in both biology and medicine
specializing in oncology, Sarah completed several
internships in various Institut Curie research
laboratories. During her time at the foundation,
Sarah had access to the cutting-edge technical
equipment and dedicated staff that have earned
Institut Curie a reputation as a paragon of
excellence.
250 14,500
medical students
AND INTERNS
HOURS OF TEACHING
VIEWPOINT
“I first learned about
palliative care during
my internship at the
institute and found
this humanist approach
to medicine very
appealing. Learning
from the skilled,
articulate team
at Institut Curie was
an eye-opening
experience that helped
me strike the right
balance between
general medicine
and my desire to work
as part of a team.”
DR. LAURE PERCHERON,
former Institut Curie
intern and doctor in
the palliative care
department at Poitiers
University Hospital
13
• ADVANCED TRAINING •
he Training Unit at Institut Curie is a team
dedicated to managing, organizing and
promoting the institute’s advanced
training mission. The unit offers a wide
variety of courses—technical,
multidisciplinary, international, general and more—
in an environment highly conducive to learning.
Young researchers and doctors gain invaluable
experience working in state-of-the-art facilities,
enabling them to pursue fulfilling scientific and
medical careers.
CONSERVING SCIENTIFIC HERITAGE
04 THE CURIE MUSEUM
TH
CELEBRATES ITS 20
ANNIVERSARY
“The Curie Museum and archives
are more than just a landmark
or history museum—the site is now
a space for sharing and spreading
knowledge. The museum’s unique
collections retrace the history of
the family with five Nobel Prizes
and the broader scientific and
social developments of the interwar
period.”
Renaud Huynh
DIRECTOR OF THE MUSEUM UNIT AND THE CNRS/
INSTITUT CURIE INSTITUT DU RADIUM ARCHIVES
E
stablished in 1994 by CNRS and Institut
Curie, the Curie Museum has become
a nexus for knowledge production and
sharing that contributes to France’s
international renown and excellence in
the fields of science and medicine. The primary
missions of the museum are to:
• Safeguard, collect and conserve the history
of the Curie family and their associates, Institut
du Radium and the Curie Foundation, as well as
radium and radioactivity in general
• Curate and classify the collections, develop tools
to improve access and study, contribute to social
science research
• Promote, exhibit and share the collections with
the widest possible audience
14 - ANNUAL REPORT 2014 - INSTITUT CURIE
Bringing the memory of the Curie family to life is
a means of transmitting the history and values of
these exceptional individuals while extending
the cultural reach of science.
The origins of the Curie Museum are found in
the collections it houses, in particular two historic
rooms—Marie Curie’s office and laboratory—that
were restored to their original state in the 1960s.
This historical landmark exhibits a vast array of
exceptional pieces—scientific instruments,
furniture, photos, books, documents and other
items—that have drawn a wide audience of
captivated visitors from across the world for over
50 years.
A guardian of collective memory and a repository
for unique scientific and cultural heritage,
MARIE CURIE AND THE GREAT WAR
The First World War centenary in 2014 provided an
ideal opportunity to honor the medical radiology
work of Marie Curie and her daughter Irène during
the conflict, as well as to highlight the pioneering
role played by Dr. Claudius Regaud, founder of the
cancer research centers. Over the course of the
year, the museum’s historical resources center
opened its archives to filmmakers, who produced
a well-received documentary drama on Marie Curie’s
work during the war. The museum also partnered
with a theater company to produce a similarly
themed stage production.
WOMEN IN SCIENCE: MARIE CURIE’S HEIRS
Research at the museum focuses on two main
topics: the scientific and medical history of Institut
du Radium and the Curie Foundation, and the
historic role of women in science and medicine.
The work of Natalie Pigeard-Micault, PhD, CNRS
engineer and head of the museum’s historical
resources center, inspired an open-air exhibition
celebrating women in science who have followed in
Marie Curie’s footsteps, held from March to October.
The exhibition profiled 25 scientists from the past
and 18 current Institut Curie experts, offering a
detailed look at both pioneering women in the
scientific community and the women who are
currently shaping science and medicine.
Dr. Pigeard-Micault, a recognized authority on
the history of women in science in the 19th and
20th centuries, also organized a number of
conferences on the topic throughout the year.
A NEXUS FOR KNOWLEDGE PRODUCTION AND SHARING
Nearly 12,500 people visited the museum in 2014
and specialist requests increased tenfold, thanks
to efforts to share historical resources with
a greater audience. The institution also added
a free app to its array of digital communication
tools, enhancing the visitor experience and
complementing the numerous events held
throughout the year for people of all ages:
theme-based tours, demonstrations, documentary
films, etc.
• CONSERVING SCIENTIFIC HERITAGE •
the museum—housed in the former Institut
du Radium, which became Institut Curie in the
1970s—has since grown to become a nexus
for knowledge production and sharing.
Nearly
12,500
VISITORS IN 2014
VIEWPOINT
“The museum is a
monument to the
history of chemistry
and physics, as well as
a tremendous homage
to Marie Curie and the
pioneers of
radioactivity, who used
their discoveries to
further science and
healthcare. Bravo!”
CHRISTOPHER CLEMENT,
Scientific Secretary,
International
Commission on
Radiological Protection
15
ACKNOWLEDGEMENTS
THANK YOU
TO OUR 180,000 DONORS
TO THE 95 PEOPLE WHO CHOSE TO DONATE PART
OR ALL OF THEIR WEALTH VIA A LEGACY GIFT,
DONATION OR LIFE INSURANCE POLICY
TO OUR PRIVATE-SECTOR PARTNERS
AG2R La Mondiale, Agence Nationale des Chèques Vacances, AstraZeneca, Audap &
Mirabaud, Bioderma, CEW, CNH Industrial, Conseil National des Centres Commerciaux,
Crédit Suisse, Fédération Française de Rugby, Fondation Apicil, Fondation Areva, Fondation
Dominique et Tom Alberici, Fondation EDF, Fondation Eric Vincenot, Fondation GDF SUEZ,
Fondation Hôpitaux de Paris – Hôpitaux de France, Fondation L’OCCITANE, Fondation
L’Oréal, Fondation MACSF, Fondation Michelin, Fondation Philanthropia, Fondation Swiss
Life, Fondation Truffaut, GDF Suez, Hôtel des ventes Drouot, Malakoff Médéric, Mutuelle
Bleue, Nikon, Pause Fruitée, The Annenberg Foundation, The Conny Maeva Charitable
Foundation, Thornburg Foundation and Truffaut,
to our public-sector partners
CNRS, European Commission, French Ministry of National Education, Higher Education and
Research, French Ministry of Social Affairs, Health and Women’s Rights, INCa, Inserm, local and
regional authorities, PSL Research University Paris, Unicancer and universities
16 - ANNUAL REPORT 2014 - INSTITUT CURIE
FUNDING MODEL
A STRONG
FUNDING MODEL
Institut Curie benefits from a diverse array of revenue sources,
affording the foundation the level of independence required
to undertake innovative programs.
activities in partnership with fellow research
organizations, which pay a portion of the personnel,
operating and investment costs. In addition, the
Research Center receives an annual basic research
subsidy from France’s higher education and
research ministry. Further funds are generated from
competitive national and international calls for
tender issued by France’s Investments for the
Future program, the European Research Council and
other institutions. The institute’s research
programs also rely on private-sector partners and
the generosity of the public.
Each year, Institut Curie makes a major effort to
collect the resources required to perform and
develop its missions from this diverse group of
financial backers. For its part, the Curie Museum is
financed by CNRS and public donations.
€324.2 M €41.8 M
total resources
180,000 DONORS
resources from private donors
and LEGACY GIFTS
17
• ACKNOWLEDGEMENTS & FUNDING MODEL •
T
he Hospital Group is a private healthcare
establishment recognized as serving the
public interest. As a result of this status,
the institute’s treatment, clinical
research, teaching and innovation
activities are primarily funded by the French social
security system. This revenue is supplemented by
income from other sources, such as billing for
patients not covered by social security,
out-of-pocket payments and outpatient day rates.
The Hospital Group also receives clinical research
and innovation funding from industrial companies,
patrons, charitable organizations, public and
semi-public organizations, and the generosity of
the public.
The Research Center operates based on a very
different funding model. The center develops
FINANCIAL INFORMATION
FINANCIAL INFORMATION
2014 was a decisive year for Institut Curie in many respects. Strategic planning aimed
at positioning the foundation as a major stakeholder in 21st century cancer research and
treatment resulted in the Board of Directors approving medical and scientific projects and
the medical-scientific program that form the core of our Corporate Project. The translational
research teams relocated to the Hospital Group, increasing interactions between doctors and
researchers, which in turn furthered the research-care continuum. And the number of donors
and testators who supported the institute in our fight against cancer increased yet again.
We would like to offer all those who donated our deepest gratitude. Finally, with regard to
asset management, we have expanded our investments as a result of the combined effect of
positive cash flow and income from financial assets.
ACCOUNTING BALANCE SHEET
ASSETS (euros)
2014
2013
230,515,290
239,599,388
1- Subscribed capital unpaid
2- Fixed assets (2.1+2.2+2.3)
2.1- Intangible fixed assets
2.2- Tangible fixed assets
2.3- Financial assets
3- Current assets (3.1+3.2.1+3.2.2+3.3+3.4)
1,555,485
1,535,670
218,798,225
228,160,542
10,161,580
9,903,176
244,593,650
241,195,160
4,475,379
3,973,723
162,770,836
164,661,756
3.2.2- Debtors due after one year
55,550,000
55,652,822
3.3- Cash at bank and in hand
21,088,040
15,836,179
3.1- Stocks
3.2.1- Debtors due within one year
3.4- Other current assets
Total assets (1+2+3)
709,395
1,070,680
475,108,940
480,794,548
LIABILITIES (euros)
2014
2013
4. Capital and reserves (4.1+4.2+4.3+4.4)
285,552,570
279,857,763
4.1- Subscribed capital
170,261,653
167,385,797
4.2- Reserves
147,841,479
142,348,425
4.3- Profit and loss brought forward from the previous years
-39,642,097
-34,409,886
4.4- Profit and loss brought forward for the financial year
5. Creditors (5.1.1+5.1.2+5.2.1+5.2.2)
5.1.1- Long term non-bank debt
5.1.2- Long term bank debt
5.2.1- Short term non-bank debt
5.2.2- Short term bank debt
Total liabilities (4+5)
18 - ANNUAL REPORT 2014 - INSTITUT CURIE
7,091,535
4,533,427
189,556,370
200,936,785
0
0
34,999,000
39,145,578
150,236,306
156,689,418
4,321,064
5,101,789
475,108,940
480,794,548
INCOME STATEMENT
Euros
2013
2014
Revenue
353,216,848.00
344,942,229.00
501,656
-150,931
Variation in stocks (1)
Other operating income
Operating income (OI)
0
0
353,718,504
344,791,298
Cost of materials and consumables
62,755,318
62,727,607
Other operating charges
96,845,083
95,390,049
153,578,343
155,090,835
Remuneration and charges (staff costs)
Gross Operating Profit or Loss (GOP/GOL)
40,539,760
31,582,807
Depreciation and value adjustments on non-financial assets
31,904,043
32,292,005
Net Operating Profit or Loss (NOP/NOL)
8,635,717
-709,198
Financial income and value adjustments on financial assets
8,821,646
8,567,823
Interest paid
3,111,576
3,319,333
Similar charges
0
0
14,345,787
4,539,292
Extraordinary income
3,410,629
104,452
Extraordinary charges
10,664,881
110,317
7,091,535
4,533,427
Profit or Loss on ordinary activities
Taxes on profits
Profit or Loss for the financial year (Net result)
(1) Positive or negative amount
INCOME AND EXPENDITURE BY PUBLIC INTEREST ASSIGNMENT
CARE
Expenditure
<
8 2%P ublic health
insurance funds
1 2%O ther income
Income
<
RESEARCH
78% on care activities, i.e., €229.1 million
5 6%Research contracts
22%on research, i.e., €65.6 million
2 6%P ublic fundraising
6%
P ublic fundraising
14% Grant from the French
Ministry of Research
4%
O ther income
H ospital operations, including clinical research
Research activities
19
• FINANCIAL INFORMATION •
Income
A private charitable foundation since 1921
26 rue d’Ulm, 75248 PARIS CEDEX 05 ­– FRANCE
Phone: +33 (0)1 56 24 55 00
Follow us on:
Together, let’s beat cancer.
www.institut-curie.org